Biocardia Inc. said an independent data safety monitoring board has found there are no safety concerns for the first 10 patients treated in the phase 3 Cardiamp cell therapy trial. The San Carlos, Calif.-based company's ongoing multicenter, double-blinded, randomized, sham-controlled phase 3 trial is expected to enroll 260 patients at up to 40 centers across the U.S. and will continue as planned. Read More
